Trusted brands in one place
Clinically proven for weight loss
Doctor-guided programs
No in-person appointments needed
Trusted brands in one place
Clinically proven for weight loss
Doctor-guided programs
No in-person appointments needed

Explore GLP-1's
News & Updates

Learn more about GLP'-1's latest news & updates

Explore By Category

All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Novo Nordisk's New Ad Agency: What It Means for You
News & Updates

Novo Nordisk's New Ad Agency: What It Means for You

Omnicom has won the U.S. media account for Novo Nordisk, the maker of Ozempic and Wegovy. While this is an advertising industry headline, it carries real implications for how GLP-1 medications are marketed and potentially priced. Here's what patients need to know.

Read More
GLP-1 Drugs for $50: Which Pharmacies Offer It
News & Updates

GLP-1 Drugs for $50: Which Pharmacies Offer It

Several major pharmacy chains now offer GLP-1 weight loss medications at dramatically reduced prices through discount programs. This guide breaks down which pharmacies participate, what's actually available at $50, and how to navigate the fine print so you're not caught off guard.

Read More
Amazon Pharmacy GLP-1s for Medicare: $50/Month
News & Updates

Amazon Pharmacy GLP-1s for Medicare: $50/Month

Amazon Pharmacy has launched a $50/month GLP-1 medication program for eligible Medicare patients, a significant shift in how older Americans can access semaglutide and similar drugs. This guide breaks down who qualifies, what's included, and how it compares to other access routes.

Read More
Lilly's 48% Revenue Surge: What It Means for You
Patient Guides

Lilly's 48% Revenue Surge: What It Means for You

Eli Lilly reported a massive 48% revenue jump, driven almost entirely by Mounjaro and Zepbound. For patients already on these medications or considering them, this growth signals important shifts in supply, pricing, and access worth understanding before your next prescription decision.

Read More
GLP-1 Drugs and Heart Attack Risk: What the Research Shows
Health and Wellness

GLP-1 Drugs and Heart Attack Risk: What the Research Shows

GLP-1 medications are best known for weight loss, but emerging research suggests they may also reduce the risk of heart attacks and other serious cardiovascular events. Here's what the evidence shows, who benefits most, and what this means if you're already on or considering a GLP-1 drug.

Read More
Why Employers Are Paying Billions for GLP-1s
News & Updates

Why Employers Are Paying Billions for GLP-1s

Bank of America's CEO recently revealed the company spends $250 million a year on GLP-1 medications for its employees. This signals a major shift in how large employers view these drugs, and it has real implications for patients trying to access and afford semaglutide or tirzepatide.

Read More
Lilly vs. Novo: What the GLP-1 Race Means for You
Patient Guides

Lilly vs. Novo: What the GLP-1 Race Means for You

Eli Lilly recently beat earnings estimates on strong demand for its injectable GLP-1 drugs, widening its lead over Novo Nordisk. For patients, this growing competition has real implications for drug availability, pricing, and future treatment options. Here's what you need to know.

Read More
Mounjaro & Zepbound Sales Surge: What It Means for You
News & Updates

Mounjaro & Zepbound Sales Surge: What It Means for You

Eli Lilly's tirzepatide medications, Mounjaro and Zepbound, are pulling ahead of Novo Nordisk's semaglutide offerings in sales. For patients weighing their GLP-1 options, this shift carries real implications for access, pricing, and what to expect from your provider. Here's what you need to know.

Read More
GLP-1 Drugs and Eye Health: What to Know
Health and Wellness

GLP-1 Drugs and Eye Health: What to Know

Emerging research suggests GLP-1 medications like semaglutide and tirzepatide may have measurable effects on eye health. Some findings point to potential benefits, while others raise questions worth discussing with your doctor. Here is what current and prospective GLP-1 patients need to know.

Read More